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abstract
PURPOSE By 2025, Kenya is estimated to experience a two-thirds increase in the incidence of breast cancer.
Local research is necessary to generate evidence to inform policy, public health, and medical practice. There
have been no longitudinal cohort studies in sub-Saharan Africa of women with and without breast cancer. Our
aim is to assess the feasibility of conducting cohort studies in Kenya that consider clinical characteristics,
socioeconomic factors, and self-care behaviors.
METHODS We initiated a short-term follow-up cohort study of women with and without a diagnosis of breast
cancer with baseline face-to-face data collection and one follow-up interview (at approximately 3 months by
telephone). We developed tailored instruments to capture demographics, socioeconomic factors, breast cancer
risk, ability to identify breast cancer symptoms, treatments received for breast cancer, and quality of life of
survivors.
RESULTS We recruited 800 women between the ages of 20 and 60 years and successfully collected baseline
data. Completeness of the data was high for demographic variables, but there was a larger proportion of missing
information for specific variables required for assessing breast cancer risk. Respondents were able to complete
standardized instruments to assess breast cancer knowledge among those without breast cancer and iden-
tification of symptoms among survivors. We were able to successfully contact approximately 80% of the
participants for follow-up.
CONCLUSION This short-term follow-up study provides evidence that women can be successfully tracked and
contacted for follow-up in the Kenyan setting and offers lessons to establish future longitudinal cohorts to identify
approaches to improve breast cancer outcomes.
J Global Oncol. © 2019 by American Society of Clinical Oncology
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INTRODUCTION
Breast cancer incidence is expected to increase
substantially in sub-Saharan Africa, and the mortality
rate among those diagnosed with breast cancer is
much higher in sub-Saharan Africa than in high-
resource settings.1-3 The breast cancer incidence
rate in Kenya is estimated at 38.3 per 100,000 women,
and the mortality rate is 17.3 per 100,000 women.1 In
the United States, the breast cancer incidence rate is
much higher, whereas the mortality rate is much lower
(0.09% and 0.01%, respectively).4 Furthermore,
women are diagnosed with breast cancer at a younger
age in Kenya, with a median age of approximately
49 years, compared with a median age of 62 years in
the United States.2,5
The anticipated growth in breast cancer incidence in
countries such as Kenya is fueled by multiple in-
terrelated factors including demographics, lifestyle,
genetics, and the environment. The Kenya National
Cancer Control Strategy (2017 to 2022) identified
several priority research areas, including research on
behavioral factors, environmental and occupational
risk factors, and treatment options, including their
effectiveness and costs.6 Although breast cancer re-
search in Kenya is providing useful insights, studies
are often limited to specific medical institutions and
usually involve small numbers of patients.7-10 Large-
scale, community-based patient cohorts are crucial to
provide findings on disease presentation, treatment
outcomes, and survivorship experiences.
In this article, we report findings on the feasibility to
initiate and conduct cohort studies to address key
research questions to improve breast cancer care in
Kenya. Our objectives were to understand barriers
related to recruitment, evaluate the ability to col-
lect high-quality baseline data to address research
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whether we could contact patients for follow-up. Findings
from this study can provide important lessons to tailor future
longitudinal studies to the local environment to ensure
successful recruitment and long-term follow-up.
METHODS
We conducted a feasibility study to inform best practices for
initiating longitudinal cohort studies in Kenya. We collected
baseline data using face-to-face interviews and collected
follow-up data via telephone approximately 3 months later.
The study included women age 20 to 60 years with and
without a diagnosis of breast cancer in separate cohorts.
We selected this age range to include both women with
a high incidence of breast cancer and those eligible for
screening. We limited inclusion in the breast cancer cohort
to those who were diagnosed within the past 3 years
(measured at the time of survey administration). We aimed
to recruit 400 women in each cohort from four counties in
Kenya, Nairobi, Kiambu, Machakos, and Nyeri, to ensure
adequate representation of women who live in urban and
rural counties.
We collected data including patient demographics, so-
cioeconomic factors, risk factors, breast cancer treatment
methods, and insurance status (Appendix Table A1).
Previously validated instruments and tools were used to
collect details on breast cancer risk and knowledge.11-14
The questionnaire was initially developed in English and
then translated into Kiswahili. Cognitive testing was per-
formed (40 women) to assess the reliability and validity of
the questionnaires.
Ethical approval for this study was obtained from the
Kenyatta National Hospital–University of Nairobi Ethics and
Research Committee and the RTI International Institutional
Review Board. We recruited women diagnosed with breast
cancer through the membership lists maintained by the
Kenya Cancer Association and the Kenya Hospices and
Palliative Care Association. We also recruited survivors of
breast cancer from Kenyatta National Hospital (the main
referral hospital in Kenya) and health care facilities and
breast cancer survivorship groups in the targeted counties.
The cohort of women without breast cancer were recruited
through the membership lists of the Kenya Cancer Asso-
ciation and the Kenya Hospices and Palliative Care As-
sociation, from health care facilities, and through general
outreach in the community. After eligibility assessment,
trained research assistants helped the women who met the
recruitment criteria to provide written informed consent to
participate in the baseline and follow-up assessments. We
included women who voluntarily gave consent. We ex-
cluded women who did not speak and understand the
study languages (English and Kiswahili) and those who
were unable to provide contact information for themselves
and next of kin. Face-to-face interviews were held either at
the same location on the same day of recruitment or at
a later time or day by appointment; consent was obtained
immediately before the interview. Participants received
a copy of the consent form and were offered nominal fi-
nancial support for interview-related expenses including
travel (up to approximately $5). The initial face-to-face data
collection was followed by a one-time follow-up interview by
telephone approximately 3 months after baseline. Women
were recruited for the baseline interview between No-
vember 2017 and April 2018, and all follow-up telephone
interviews were completed by July 2018.
We began performing data processing and analysis in the
field by evaluating data completeness and ensuring quality
control. Hard copies of data from paper instruments were
then entered into an electronic database with only a study-
assigned identifier to ensure patient anonymity. Additional
checks were conducted to identify missing values, out-of-
range inputs, and validity of the survey skip patterns.
Queries were resolved by reviewing the paper records. Data
on women with and without breast cancer are presented
separately to reflect their distinct groups. Our goal was not
to compare the two cohorts but to learn about the expe-
riences of these women to inform screening, diagnosis, and
treatment of breast cancer. We present descriptive statistics
on demographics, socioeconomic factors, insurance, em-
ployment status, comorbidities, and treatment of breast
cancer. We collected information on a wide range of
comorbidities, including cardiovascular conditions, de-
pression, and weight issues. To facilitate analyses, we
developed a summary measure of the total number of
conditions reported. We also present summary measures
for some of the key variables that are required to generate
breast cancer risk scores.15,16 For each variable, we report
the proportion of missing values to highlight the com-
pleteness of the information available for analysis. We
present this information for both cohorts to evaluate the
ability to collect this information from women in Kenya.
For women without a breast cancer diagnosis, we present
the level of breast cancer knowledge by analyzing the
concepts in the Breast Cancer Awareness Measure
(BCAM). In addition, we explored the quality of life among
survivors of breast cancer using the standardized scoring
algorithm for the Functional Assessment of Cancer
Therapy–Breast Cancer Symptom Index-16 (FBSI-16;
Version 2). The FSBI-16 contains 16 response items for
which respondents select one response from the following
five available options: “not at all,” “a little bit,” “somewhat,”
“quite a bit,” and “very much.” On the basis of how an item
is phrased, we either report the percentage who responded
“not at all” and “a little bit” or “quite a bit” and “very much.”
To assess our ability to re-establish contact with partici-
pants to conduct longitudinal studies in the future, we
report the percentage of women in both cohorts who
participated in the follow-up telephone interviews. We
assigned those with whom we were unable to follow up to
one of the following six categories: died during follow-up
period, refused or unavailable for follow-up interview,
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TABLE 1. Demographic Characteristics by Survey Cohort
Characteristic
Women With Breast Cancer
(n = 400)
Women Without Breast Cancer
(n = 400)
No. % No. %
Age, years, mean* 46.1 39.2
Place of residence
Nairobi, Mombasa, other cities 125 31.3 82 20.5
Other towns 70 17.5 54 13.5
Countryside 204 51.0 261 65.3
Outside Kenya 1 0.3 2 0.5
Missing 0 0.0 1 0.3
Educational attainment
None 10 2.5 6 1.5
Primary 136 34.0 101 25.3
Secondary/vocational 149 37.3 154 38.5
College 70 17.5 109 27.3
University 33 8.3 26 6.5
Missing 2 0.5 4 1.0
Marital status
Never married 41 10.3 79 19.8
Married/living together 244 61.0 226 56.5
Divorced/separated 68 17.0 63 15.8
Widowed 46 11.5 30 7.5
Missing 1 0.3 2 0.5
Religion
Roman Catholic 112 28.0 117 29.3
Protestant/other Christian 281 70.3 270 67.5
Muslim 6 1.5 8 2.0
Other 0 0.0 3 0.8
Missing 1 0.3 2 0.5
Employment status
Employed or working for pay 132 33.0 258 64.5
Unemployed; plan to seek employment 134 33.5 86 21.5
Unemployed; do not plan to seek employment 127 31.8 49 12.3
Missing 7 1.8 7 1.8
Type of insurance coverage (multiple plans allowed; not mutually exclusive)
None 119 29.8 199 49.8
National Hospital Insurance Fund 268 67.0 187 46.8
Private insurance 50 12.5 38 9.5
No. of comorbid conditions or ailments
Mean 1.60 0.75
0 22 5.5 211 52.8
1-2 320 80.0 164 41.0
3-4 46 11.5 23 5.8
. 5 12 3.0 2 0.5
NOTE. All values are numbers and percentages, unless noted otherwise.
*Age was missing for four women with breast cancer and one woman without breast cancer.
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problem communicating, hospitalized as a result of an
illness, traveling and cannot be reached, or other reason
including could not be reached by telephone.
RESULTS
We successfully recruited 800 women, and as shown in
Table 1, the level of completeness was high across all
demographic variables, with missing values of 2% or less.
The average age of the women in our study was 46 years for
women with breast cancer and 39 years for those without
a diagnosis of breast cancer. The majority of the partici-
pants in both cohorts indicated they were from the coun-
tryside; the next most frequently cited locations were major
cities such as Nairobi and Mombasa. The most common
level of educational attainment for both groups was sec-
ondary or vocational school (women with breast cancer,
37.3%; women without cancer, 38.5%), followed by primary
school for women with breast cancer (34.0%) and college
for women without breast cancer (27.3%). Most of the
participants in both cohorts were married and considered
themselves to be Protestants. Women without breast
cancer were twice as likely to be employed (64.5%) com-
pared with women with breast cancer (33.0%), although
approximately one third of these survivors planned to
pursue employment in the future. Nearly 70% of women
with breast cancer had insurance compared with ap-
proximately half of the women without breast cancer. The
mean number of comorbid conditions was 1.60 for women
with breast cancer and 0.75 for those without breast
cancer. The vast majority of women with breast cancer
reported one to two comorbid conditions (80.0%), and
most participants without breast cancer (52.8%) did not
report any conditions.
In Table 2, we report the descriptive statistics of some of the
key variables that are required to generate breast cancer
risk scores. We present data for women with and without
breast cancer to assess availability of the data elements; we
do acknowledge that risk assessment for breast cancer is
not relevant to those already diagnosed with breast cancer.
Current age, first-degree relative with breast cancer, and
age at first birth were generally complete, with less than 1%
of values missing for both cohorts. As expected, many more
women with breast cancer reported undergoing biopsies
than women without breast cancer; however, 3.8% of
women without breast cancer did not respond to this
question. There were also barriers to complete data col-
lection for first menstruation (ie, menarche). Overall, 12.3%
of women with breast cancer did not know their age at
menarche, as opposed to 4.5% of those without breast
cancer.
Figure 1 presents results from the BCAM that was ad-
ministered to women without breast cancer to ascertain
their knowledge of breast cancer warning signs, symptoms,
and risk factors. The vast majority of participants (81.5%)
identified a lump in the breast as a warning sign of breast
cancer, followed by discharge from the nipple (75.3%),
bleeding from the nipple (74.5%), and dimpling of the
breast skin (60.8%). Conversely, the symptoms that were
least often cited were a nipple rash (42.0%), the nipple
pulling inward (40.0%), and change in nipple position (36.
5%). As shown, a plurality of participants (36.8%) reported
checking their breasts every week; however, the second
most common response was “rarely or never” (33.0%).
Furthermore, more than three fifths of women without
breast cancer (63.6%) reported feeling “very confident” or
“fairly confident” in their ability to detect such a change.
In Table 3, we report on the clinical and treatment-related
variables pertaining to women with breast cancer. Themost











No. % No. %
Age, years
Mean 46.1 39.2
, 45 187 46.8 307 76.8
≥ 45 209 52.3 92 23.0
Missing 4 1.0 1 0.3
No. of first-degree relatives with breast cancer
0 327 81.8 351 87.8
1 66 16.5 43 10.8
≥ 2 4 1.0 2 0.5
Missing 3 0.8 4 1.0
No. of breast biopsies
0 187 46.8 380 95.0
1 121 30.3 1 0.3
≥ 2 85 21.3 0 0.0
Missing 7 1.8 15 3.8
Age at menarche, years
≥ 14 257 64.3 276 69.0
12-13 84 21.0 94 23.5
, 12 8 2.0 7 1.8
Did not know 49 12.3 18 4.5
Missing 2 0.5 5 1.3
Age at first live birth, years
No live births 19 4.8 40 10.0
, 20 95 23.8 105 26.3
20-24 170 42.5 169 42.3
25-29 84 21.0 61 15.3
≥ 30 29 7.3 22 5.5
Missing 3 0.8 3 0.8
NOTE. All values are numbers and percentages, unless noted otherwise.
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common disease stages at diagnosis were stage II (39.5%)
and stage III (30.3%); 11.8% of women could not identify
their stage. Almost 80% of women with breast cancer were
still in treatment at the time of the survey administration.
The vast majority of women (93.0%) had received che-
motherapy, and other commonly cited tests and treatments
were mastectomy (74.5%) and radiotherapy (53.0%).
Among those who knew their receptor status, the most
common were human epidermal growth factor receptor 2
positive (14.8%) and endocrine receptor positive (8.3%).
More than two thirds of the women with breast cancer
(68.7%) did not know their receptor status. Themean FBSI-16
score among our study participants was 19.2 (Fig 2). In the
context of the FBSI-16, a patient who scores 0 is severely
symptomatic, and a patient who scores 64 is asymptomatic.
The most commonly cited FBSI-16 symptom or conse-
quence of breast cancer was the inability to work (37.9%)
or to meet the needs of the family (35.9%). Approximately
one fourth of women also reported that they experience













Change in nipple position
Nipple pulling inward
A nipple rash
Change in nipple size
Change in breast shape
Change in breast size
Change in breast skin color
Pain in one breast
Puckering or dimpling of the breast skin
Bleeding from the nipple
Abnormal discharge from the nipple
A lump in the breast
% of Women Without Breast Cancer
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At least once every 6 months
At least once a month
Rarely or never
At least once a week
% of Women Without Breast Cancer
How often do you check your breasts?
FIG 1. Responses to the Breast Cancer Awareness Measure.
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Table 4 lists the results from our follow-up survey. We
were able to contact 87.8% of the participants with
breast cancer or their next of kin for follow-up and 79.
0% of the participants without breast cancer approxi-
mately 3 months after our initial baseline data collec-
tion. The most common reason we were unable to
contact participants in the breast cancer cohort was
because they had died (4.8%). For women without
breast cancer, the most frequent reason was general
refusal (11.5%). This code covered responses ranging
from “refused to answer questions” to “too busy during
the day to take calls.”
DISCUSSION
We conducted this short follow-up prospective cohort study
of women with and without a diagnosis of breast cancer in
Kenya to evaluate the approach of using face-to-face in-
terviews and follow-up telephone calls to collect longitu-
dinal data. We were able to successfully enroll our target of
400 women per cohort and collected baseline information
for all participants. Data completeness was high for de-
mographic variables, and women were able to describe
their experiences with both breast cancer screening and
treatment. Most of the women were also able to provide
details on data elements required for breast cancer risk
assessment; however, there was a large proportion of
missing information for age of menarche. This data element
was not available in approximately 6% of women without
breast cancer and in a much higher rate of up to 13%
among women with breast cancer. Survivors of breast
cancer were substantially older (52% were age 45 years or
older) than the women without a cancer diagnosis (23%
were age 45 years or older), and there were also some
differences in education level and area of residence, which
may have influenced the variation seen across these two
cohorts. Furthermore, more than two thirds of the women
reported that they did not know their receptor status; it is
unclear whether they either did not recall being tested or
had not been tested. The reasons for missing or unknown
data should be additionally evaluated in future studies. In
this study, we attempted to collect key variables related to
breast cancer risk, and in follow-up studies, we can expand
to include a broader range of factors including the use of
hormonal contraceptives in Kenya.
Our findings are also encouraging because women were
able to provide the information required for the standard-
ized items included in the BCAM and the FBSI-16. These
results support prior research that also validated the use of
the BCAM to assess breast cancer knowledge and barriers
among Kenyan women.17 Many of the women without
a diagnosis of breast cancer were generally aware of the
symptoms of breast cancer—especially common symp-
toms such as a lump, abnormal discharge, and bleeding—
but less than half were aware of the risk posed by other
symptoms such as change in nipple size and position.
Importantly, approximately 20% of these women were
unaware that the presence of a lump in the breast could be
indicative of breast cancer. This lack of universal knowl-
edge clearly highlights the need for additional education
and awareness of breast cancer symptoms. Although more
than half of the women interviewed reported performing
breast self-exams at least monthly and the majority were
confident in their ability to identify breast changes, we are
unable to assess the actual skill and reliability of the
women’s self-assessment. A longitudinal follow-up study













Did not know 47 11.7
Missing 3 0.8
Elapsed time since last cancer treatment
I am still receiving treatment 319 79.6
, 1 year ago 29 7.2
1 year ago to , 2 years ago 21 5.2
. 2 years ago 20 5.0
I have not been treated for cancer 8 2.0
Missing 3 0.8




Breast reconstruction 14 3.5
Hormonal therapy 109 27.2
Immunotherapy 45 11.2
Bone-directed therapy 15 3.7
Physical therapy 36 9.0
Breast cancer receptor status
Endocrine receptor (estrogen or progesterone receptor)–positive
breast cancer
33 8.3
HER2-positive breast cancer 59 14.8
Triple negative, not positive to receptors for estrogen 21 5.3
Triple negative, positive to receptors for estrogen 10 2.5
Inflammatory breast cancer 2 0.5
Did not know 275 68.7
Abbreviation: HER2, human epidermal growth factor receptor 2.
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will be required to systematically monitor and assess
women’s behavior and ability to identify breast cancer to
reduce the frequency of late-stage presentation of patients
with breast cancer that currently exists in Kenya.18 Simi-
larly, additional research is also required to explore the
findings from the FBSI-16 assessment. Women with breast
cancer experience a range of issues during and after
treatment, and their inability to work and care for their
families could be minimized by optimal interventions and
support systems to improve their quality of life.
There is limited research on cohort studies, and longitu-
dinal cohorts have not been previously established in Kenya
and many other sub-Saharan African countries because of
their high cost and challenges in maintaining participant
contact.19-21 With increased mobile technology, we pre-
sume that continued contact with participants during
a study period is feasible and can be accomplished in
a more cost-effective manner than previously possible.22,23
We were able to successfully recontact a large proportion of
the participants in both cohorts of this study (88% of the
women with breast cancer and 79% of those without breast
cancer). We were unable to reach approximately 5% of the
breast cancer cohort despite multiple attempts to contact
the patients as well as next of kin by telephone. In the
future, we suggest collecting provider information (physi-
cian name or hospital) to improve the follow-up rate and to
identify the women’s status. Among those who participated

















I have mouth sores
I have been short of breath
I have nausea
I am bothered by hair loss
I feel ill
I am bothered by side effects
I am sleeping well
I worry that my condition will get worse
I am content with my quality of life
I am able to enjoy life
I have a lack of energy
I have pain
I feel fatigued
I have bone pain
I have trouble meeting my family's needs
I am able to work
(Mean FBSI-16 Score=19.2)
Reporting percentage responses for:
"Not at all" or "a little bit"
"Quite a bit' or "very much"
FIG 2. Functional Assessment of Cancer Therapy–Breast Cancer Symptom Index-16 (FBSI-16) mean score and response items.
TABLE 4. Response to Follow-Up Telephone Interview
Response
Women With Breast Cancer
(n = 400)
Women Without Breast Cancer
(n = 400)
No. % No. %
Participant responded to follow-up telephone interview 351 87.8 316 79.0
Participant responded 345 86.3 316 79.0
Next of kin responded 6 1.5 0 0.0
Reason participant was not interviewed
Died during follow-up period (eg, died of meningitis) 19 4.8 2 0.5
Refused or unavailable for follow-up interview (eg, reached but
refused to talk)
4 1.0 46 11.5
Problem communicating (eg, difficulty speaking as a result of cough) 3 0.8 3 0.8
Hospitalized as a result on an illness (eg, currently sick in the hospital) 3 0.8
Traveling and cannot be reached (eg, out of the country) 4 1.0 2 0.5
Other reasons including cannot be reached by telephone (eg,
technical issues, did not respond)
19 4.8 28 7.0
Short Title
Journal of Global Oncology 7
Downloaded from ascopubs.org by 197.136.150.10 on October 23, 2020 from 197.136.150.010
Copyright © 2020 American Society of Clinical Oncology. See https://ascopubs.org/go/authors/open-access for reuse terms.
12% refused the follow-up interview when contacted by
telephone. Anecdotal evidence gained by the interviewers
suggests that these women were not willing to engage in
long-term follow-up because they did not see themselves as
sick. Lack of awareness of breast cancer risk and stigma
associated with breast cancer may limit women’s willing-
ness to participate in cohort studies, especially those
without a breast cancer diagnosis.24 Therefore, appropriate
tools and approaches are required to communicate the
research procedures along with the benefits and potential
drawbacks of participating in longitudinal cohort studies.
A key strength of this study is that we were able to collect
detailed information from 800 women to identify barriers to
breast cancer screening and treatment to reduce the
burden from this disease among Kenyan women. Although
we were able to show that many important data elements
can be collected, the quality of this information was not
assessed. For instance, there could be response bias be-
cause women may have provided socially or personally
desirable answers, such as indicating that they were very
confident in identifying breast cancer signs and symptoms.
In addition, women’s responses can be subject to recall
bias, especially for treatment responses if breast cancer
treatment occurred several years before the study in-
terviews. In the future, we could request approval from
participants to access medical records pertaining to their
breast cancer treatment so clinical data are available to
evaluate completeness and accuracy of patient-reported
risk factors and treatment modalities. In addition, all women
who participated in this cohort study were identified from
the regions within or in close proximity to Nairobi county,
and therefore, our findings may not be generalizable to the
entire country.
The findings from this study can offer important lessons for
future cohort studies in Kenya and other sub-Saharan
African countries. Our feasibility study of 800 participants
with short-term follow-up provides the evidence that women
can be tracked and contacted to initiate longitudinal cohort
studies. Local evidence on breast cancer prevention, screen-
ing, and treatment is critical for tailored interventions to
address the growing burden of breast cancer in sub-Saharan
African countries.
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APPENDIX











√ √ Kenya Demographic and Health Survey (2014)11
Breast cancer risk assessment √ √ Breast Cancer Risk Assessment Tool–US National
Cancer Institute, https://bcrisktool.cancer.gov12
Insurance status and employment √ √ Investigator-developed questions
Breast cancer knowledge √ Breast Cancer Awareness Measure Toolkit Updated
September 2, 2011 (Modified)13
Breast cancer symptom
assessment
√ Investigator-developed questions and the National
Comprehensive Cancer Network Functional
Assessment of Cancer Therapy–Breast Cancer
Symptom Index-16 (Version 2), http://www.facit.
org/facitorg/questionnaires14
Qualitative feedback: questions to
obtain suggestions on how to
improve self-care behaviors and
health care delivery
√ √ Investigator-developed questions
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